ExoNostic proposes the development of an innovative, disposable diagnostic kit specifically designed for early detection of Triple-Negative Breast Cancer (TNBC) at the point of care (POC). TNBC is one of the most aggressive forms of breast cancer, characterized by limited treatment options and poorer patient outcomes, especially when diagnosed at advanced stages. Early detection is crucial for significantly improving patient survival and quality of life. Our diagnostic kit employs advanced semiconductor biosensor technology to rapidly and accurately detect cancer-specific biomarkers directly from small blood samples. Unlike conventional methods such as invasive biopsies or mammograms, which require extensive, costly, and centralized healthcare infrastructure, ExoNostic's solution enables quick, reliable testing directly at clinical settings or remote locations. A distinctive feature of our diagnostic kit is its lab-on-a-chip design, which offers enhanced sensitivity and specificity compared to traditional approaches. This technology removes the dependency on centralized laboratory equipment, thus making high-quality diagnostics accessible and affordable, particularly beneficial for resource-limited or underdeveloped regions. By significantly reducing barriers related to cost, complexity, and time associated with cancer diagnostics, ExoNostic's innovation democratizes early detection, contributing to improved health outcomes. Furthermore, this project aligns closely with Innovate UK's strategic objectives by supporting advancements in the UK's semiconductor industry, fostering domestic expertise, and creating pathways for further healthcare diagnostic innovations.